208 related articles for article (PubMed ID: 23055343)
1. Aberrant promoter methylation of the RASSF1A and APC genes in epithelial ovarian carcinoma development.
Bhagat R; Chadaga S; Premalata CS; Ramesh G; Ramesh C; Pallavi VR; Krishnamoorthy L
Cell Oncol (Dordr); 2012 Dec; 35(6):473-9. PubMed ID: 23055343
[TBL] [Abstract][Full Text] [Related]
2. Promoter hypermethylation profile of ovarian epithelial neoplasms.
Makarla PB; Saboorian MH; Ashfaq R; Toyooka KO; Toyooka S; Minna JD; Gazdar AF; Schorge JO
Clin Cancer Res; 2005 Aug; 11(15):5365-9. PubMed ID: 16061849
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic alteration of p16 and retinoic acid receptor beta genes in the development of epithelial ovarian carcinoma.
Bhagat R; Kumar SS; Vaderhobli S; Premalata CS; Pallavi VR; Ramesh G; Krishnamoorthy L
Tumour Biol; 2014 Sep; 35(9):9069-78. PubMed ID: 24913706
[TBL] [Abstract][Full Text] [Related]
4. Methylation profile of BRCA1, RASSF1A and ER in Vietnamese women with ovarian cancer.
Vo LT; Thuan TB; Thu DM; Uyen NQ; Ha NT; To TV
Asian Pac J Cancer Prev; 2013; 14(12):7713-8. PubMed ID: 24460357
[TBL] [Abstract][Full Text] [Related]
5. Quantitative detection of RASSF1A DNA promoter methylation in tumors and serum of patients with serous epithelial ovarian cancer.
Bondurant AE; Huang Z; Whitaker RS; Simel LR; Berchuck A; Murphy SK
Gynecol Oncol; 2011 Dec; 123(3):581-7. PubMed ID: 21955482
[TBL] [Abstract][Full Text] [Related]
6. BRCA1 promoter hypermethylation and protein expression in ovarian carcinoma--an Indian study.
Shilpa V; Bhagat R; Premalata CS; Pallavi VR; Ramesh G; Krishnamoorthy L
Tumour Biol; 2014 May; 35(5):4277-84. PubMed ID: 24385383
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological implications of inactivation of RASSF1A in serous epithelial ovarian cancers.
Ma L; Guo Q; Ma Y; Liu FR; Shen XY
Eur J Gynaecol Oncol; 2009; 30(4):370-4. PubMed ID: 19761124
[TBL] [Abstract][Full Text] [Related]
8. Relationship between promoter methylation & tissue expression of MGMT gene in ovarian cancer.
Shilpa V; Bhagat R; Premalata CS; Pallavi VR; Ramesh G; Krishnamoorthy L
Indian J Med Res; 2014 Nov; 140(5):616-23. PubMed ID: 25579142
[TBL] [Abstract][Full Text] [Related]
9. Prognostic role of APC and RASSF1A promoter methylation status in cell free circulating DNA of operable gastric cancer patients.
Balgkouranidou I; Matthaios D; Karayiannakis A; Bolanaki H; Michailidis P; Xenidis N; Amarantidis K; Chelis L; Trypsianis G; Chatzaki E; Lianidou ES; Kakolyris S
Mutat Res; 2015 Aug; 778():46-51. PubMed ID: 26073472
[TBL] [Abstract][Full Text] [Related]
10. [Methylation of selected tumor-supressor genes in benign and malignant ovarian tumors].
Cul'bová M; Lasabová Z; Stanclová A; Tilandyová P; Zúbor P; Fiolka R; Danko J; Visnovský J
Ceska Gynekol; 2011 Sep; 76(4):274-9. PubMed ID: 22026068
[TBL] [Abstract][Full Text] [Related]
11. [Hypermethylation of promoter region of RASSF1A gene in ovarian malignant epithelial tumors].
Ma L; Zhang JH; Liu FR; Zhang X
Zhonghua Zhong Liu Za Zhi; 2005 Nov; 27(11):657-9. PubMed ID: 16438885
[TBL] [Abstract][Full Text] [Related]
12. Aberrant hypermethylation of RASSF1A promoter in ovarian borderline tumors and carcinomas.
Choi YL; Kang SY; Shin YK; Choi JS; Kim SH; Lee SJ; Bae DS; Ahn G
Virchows Arch; 2006 Mar; 448(3):331-6. PubMed ID: 16315018
[TBL] [Abstract][Full Text] [Related]
13. Frequent promoter hypermethylation of the APC and RASSF1A tumour suppressors in parathyroid tumours.
Juhlin CC; Kiss NB; Villablanca A; Haglund F; Nordenström J; Höög A; Larsson C
PLoS One; 2010 Mar; 5(3):e9472. PubMed ID: 20208994
[TBL] [Abstract][Full Text] [Related]
14. Aberrant Promoter Hypermethylation of RASSF1a and BRCA1 in Circulating Cell-Free Tumor DNA Serves as a Biomarker of Ovarian Carcinoma.
S SK; Swamy SN; Premalatha CS; Pallavi VR; Gawari R
Asian Pac J Cancer Prev; 2019 Oct; 20(10):3001-3005. PubMed ID: 31653147
[TBL] [Abstract][Full Text] [Related]
15. Aberrant promoter hypermethylation and silencing of the critical 3p21 tumour suppressor gene, RASSF1A, in Chinese oesophageal squamous cell carcinoma.
Wong ML; Tao Q; Fu L; Wong KY; Qiu GH; Law FB; Tin PC; Cheung WL; Lee PY; Tang JC; Tsao GS; Lam KY; Law S; Wong J; Srivastava G
Int J Oncol; 2006 Mar; 28(3):767-73. PubMed ID: 16465383
[TBL] [Abstract][Full Text] [Related]
16. Methylation in the p53 promoter in epithelial ovarian cancer.
Chmelarova M; Krepinska E; Spacek J; Laco J; Beranek M; Palicka V
Clin Transl Oncol; 2013 Feb; 15(2):160-3. PubMed ID: 22855178
[TBL] [Abstract][Full Text] [Related]
17. Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients.
Dulaimi E; Hillinck J; Ibanez de Caceres I; Al-Saleem T; Cairns P
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6189-93. PubMed ID: 15448006
[TBL] [Abstract][Full Text] [Related]
18. Identification of tumour-specific epigenetic events in medulloblastoma development by hypermethylation profiling.
Lindsey JC; Lusher ME; Anderton JA; Bailey S; Gilbertson RJ; Pearson AD; Ellison DW; Clifford SC
Carcinogenesis; 2004 May; 25(5):661-8. PubMed ID: 14688019
[TBL] [Abstract][Full Text] [Related]
19. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours.
Agathanggelou A; Honorio S; Macartney DP; Martinez A; Dallol A; Rader J; Fullwood P; Chauhan A; Walker R; Shaw JA; Hosoe S; Lerman MI; Minna JD; Maher ER; Latif F
Oncogene; 2001 Mar; 20(12):1509-18. PubMed ID: 11313894
[TBL] [Abstract][Full Text] [Related]
20. Association between RASSF1A promoter methylation and ovarian cancer: a meta-analysis.
Shi H; Li Y; Wang X; Lu C; Yang L; Gu C; Xiong J; Huang Y; Wang S; Lu M
PLoS One; 2013; 8(10):e76787. PubMed ID: 24116157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]